每经记者丨肖鸿月 每经编辑丨叶峰 ｜2026年1月16日星期五｜ NO.1 嘉实基金17只产品同日公告分红 公募排排网最新数据显示，截至1月13日，今年以来已有145家公募机构参与A股上市公司调研活动，覆 盖26个申万一级行业中的154只个股，累计调研次数高达999次。 从年初公募机构的调研来看，计算机、电子、医药生物等行业成为热门调研领域，其中，数字人民币、 人工智能、机器人、脑机接口、商业航天等前沿领域最受关注。 1月14日，嘉实基金一次性发布17份基金收益分配公告，包含主动权益、债券、被动指数等多类产品。 具体来看，主动权益类基金中，嘉实主题精选、嘉实增长混合、嘉实量化阿尔法等多只产品公告分红。 其中，嘉实主题精选在2025年已实施4次分红。自成立以来累计分红总额超100亿元。 NO.2 有"老基金"触发比例配售 1月14日，中欧基金发布公告，截至2026年1月12日，中欧小盘成长混合的基金资产净值已超过规模控制 上限20亿元，根据规模控制公告的规定，管理人将对2026年1月12日当日的有效申购申请采用比例确认 的原则给予部分确认，确认比例为47.843581%。 一般来说，比例配售通常发生在新发基金首 ...

Group 1 - The core point of the article highlights the dramatic turnaround of the Wanjiacong ZHONGZHENG Hong Kong Stock Connect Innovative Drug ETF, which achieved a remarkable year-to-date return of 114.01%, ranking first among all funds in the market [1][3] - The ETF, established in September 2022, initially suffered a significant excess loss of 52%, indicating a poor performance compared to its benchmark [2][3] - The fund's cumulative return since inception is 79.94%, which lags behind its benchmark by over 52 percentage points, showcasing a substantial tracking error for a passively managed ETF [3][4] Group 2 - The tracking error stemmed from poor initial positioning during the fund's launch, coinciding with a bearish market environment, leading to missed opportunities during a subsequent market rebound [4][5][7] - The fund's management team failed to establish positions promptly, resulting in a net asset value that lagged behind the benchmark index by nearly 27 percentage points [7] - The eventual success of the fund was attributed more to favorable market conditions in the innovative drug sector rather than superior management skills, highlighting a reliance on market luck [7][8] Group 3 - The article reflects on the historical context of Wanjiacong's fund management, tracing back to its origins as a pioneer in index investing in China, which faced strategic setbacks over the years [8][9] - In recent years, the company has aggressively expanded its index fund offerings, launching 43 new products from 2023 to 2025, indicating a strategic shift towards prioritizing index business [10][12] - However, this rapid expansion has led to operational challenges, with nearly half of its index funds underperforming their benchmarks, suggesting systemic issues in investment processes and risk management [13][14] Group 4 - The performance of actively managed funds under Wanjiacong also reflects weaknesses, with some funds showing significant losses and failing to capitalize on market trends, indicating broader issues in research and investment capabilities [15][16] - The article emphasizes the need for the company to address the gap between its ambitious goals and operational realities to avoid repeating past mistakes in its investment strategy [20]